Floatz logo

shr0302

Peripheral T Cell Lymphoma

Fudan UniversityPhase 2Active
CCC
55/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
73/ 100

Competitive context

135 Active assets in the Peripheral T Cell Lymphoma cohort.

Asset / SponsorPhaseRating
PREDNISONE TABLETS
Tarapeutics Science Inc.
Phase 4BBB
Pralatrexate
Peking University People's Hospital
Phase 4BBB
Inno-206
BeBetter Med Inc
Phase 4BBB
(+)-VINCRISTINE
BeBetter Med Inc
Phase 4BBB
Cyclophosphamide
Tarapeutics Science Inc.
Phase 4BBB

View all 50 →

Same molecule, other indications

shr0302 is also rated in:

immune system disorderDormant
CCC
Indicative ·
53 / 100
View asset →
refractory malignant neoplasmDormant
CCC
Indicative ·
53 / 100
View asset →
ImmunomodulationDormant
CCC
Indicative ·
53 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →